

Cancer Center Update

Rick Van Etten, MD PhD
Director, Chao Family Comprehensive Cancer Center
Senior Associate Dean and Associate Vice Chancellor for Cancer
University of California, Irvine

Today's Retreat

- We're glad you're here!
- > 350 participants!
- The Retreat goals are **communication and interaction**
- Agenda
 - Science & Policy
 - Clinical presentations
 - CHOC
 - Cultural Awareness & Humility in Research
 - Lunch with discussions
 - Concurrent Breakout Sessions
 - AI
 - Implementation Science
 - Tumor Immunology
 - Community Outreach & Engagement
 - Shared Resources
 - Posters & Flash Talks (\$\$\$)

We want your input! Your feedback is important!

• More science talks



03 Agenda AM

8:00 am	Registration & Continental Breakfast	Vista Lawn
8:35 am	Director's Welcome & Overview Richard Van Etten, MD, PhD	
9:30 am	Science & Policy Presentations Advancing Tobacco Policy Research to Reduce Disparities Denise Pagan, PhD	
	3D Spheroid DNA-Encoded Library Screening Technology: Hit Finding on the STING Pathway Brian Paegel, PhD	
	How do Statins Trigger AML Cell Death? David Fruman, PhD	
10:15 am	Coffee Break	
10:30 am	Clinical Presentations Adding Piraravatin to Venetoclax-based Therapy for Leukemias: An Experience in Drug Repurposing Elizabeth Brem, MD	
	Biliary Exosomes Unveil KP07 and SLK as Targetable Oncogenic Drivers in Cholangiocarcinoma Reed Ayabe, MD, PhD	
	Chemoprevention Clinical Trials at UCI: Past, Present, Future Jason Zek, DO	
11:15 am	CHOC Presentations Pegaspargase Therapy in Acute Lymphoblastic Leukemia: Drug Monitoring and Toxicity Van Nguyen, MD	
	Regulatory T Cells in CVL and CVHD Post-Allogeneic Stem Cell Transplant for High-Risk Acute Leukemia Bilal Sheikh-Chauhan, MD	
11:35 am	Cultural Awareness and Humility in Research Ursula Worsham, EdD	
11:35 am	Pre-Lunch Announcement	

• Cultural appropriateness




• Opportunities for student input

04 Lunch & Discussions

12:00 pm	Lunch, Optional Discussion & Posters	Vista Lawn
	 Cliffs Community Think Tank (Optional) Office of COE & Community Members	
	Join us to engage with COE leaders on your projects <ul style="list-style-type: none"> Consult with community experts Collaborate and network Prepare for new NCI community engagement expectations Strengthen the community relevance of your research Get support for community-centered research 	
	 Wedge Trainee Voices (Optional) Ursula Worsham, EdD AD for CDI Edward Nelson, MD AD for CRTEC Claudia Benavente, PhD Deputy AD for CRTEC	
	We want to hear from you. Your experience matters. <ul style="list-style-type: none"> Join us to share your lived experience at UCI Irvine Your input helps us improve and create new programs What do you need to succeed at UCI Irvine? How can the cancer center help you succeed? We look forward to hearing from you! 	

• Program-focused Breakout Sessions

05 Breakout Sessions

1:30 pm	Pre-Breakout Session Announcement Marian Waterman, PhD	
1:45 pm	Concurrent Breakout Sessions Select one to attend	
	 BIDD Breakwater The Future Scope of AI and Machine Learning In the CRCCC Vinodh Capagan, MD, PhD & Brian Paegel, PhD Join us to discuss integration of AI into cancer research, focusing on applications in imaging and drug discovery.	
	 CC Wedge Using Implementation Science to Accelerate Impact: Insights from Digital Health Stephen Schueller, PhD Join us to discuss the values of Implementation Science, a growing area of interest in Cancer Control with particular focus on Digital Health	
	 SPT Cliffs Tumor Immunology & Novel Therapeutic Approaches Angela Fleischman, MD, PhD & John Lowengrub, PhD Join us to discuss collaborative grants with a focus on tumor immunology and novel cancer therapeutics. Come with your ideas!	
2:45 pm	Coffee Break	

• Presentation on AI

• Shorter Flash Talks

06 Agenda PM

4:00 pm	Poster Flash Talks	
	09: Eye TAC: Bypassing an E3 Ligase for Target Protein Degradation Cody Loy PI: Darci Trader, PhD	
	26: Relationship Between Cytokines, Brain Derived Neurotrophic Factor, and Cognitive Impairment in Adolescent and Young Adult Cancer Patients Juta Trudeas PI: Alexandre Chan, PharmD, MPh	
	64: Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients with Solid Tumors Zachary Arter, MD PI: Peter Kaiser, PhD	
	06: Targeting of Mitochondrial Protein Magmas Enhances Sensitivity to GBM Treatment Javier Lopez Daniela Sotia, MD, PhD	
	36: Empower Latinx: Empowering Hispanic Patient's Lung Cancer Screening Uptake Mahmud Bharucha PI: Geleesh Sadigh, MD	
	58: A Phase I Study of the Combination of Piraravatin (Pira) with Gemtuzumab and Nab-paclitaxel in Patients with Unresectable Pancreatic Adenocarcinoma (UPDAC) Sennifer Valerin, MD, PhD	
4:30 pm	Concurrent Poster Session, Reception & Awards	
	Poster Session & Judging Coastal	
	Reception & Awards Breakwater Terrace	
	Your feedback is important to us. Take the survey.	

CFCCC P30 renewal status

- Received official notification of renewal of CCSG on Feb. 25, 2022
 - *Outstanding* ratings in 4 of the 6 Essential Characteristics
- Five-year funding period is through Jan. 31, 2027
- We are finishing our third year on the current grant
- Next competing renewal application will be due Jan. 25, 2026
- **New CCSG guidelines coming out September 2025**



Physical Space *(Outstanding)*

CFCCC laboratory space



Sprague Hall (Irvine campus)


- 83,000 sf, vivarium in basement
- 3rd floor: Genomics Research and Technology Hub (**GRTHub**) and Biobehavioral Shared Resource (**BBSR**)
- Current occupants: 25 CFCCC members

Shanbrom Hall (Orange campus)


- Second floor assigned to CFCCC
- ~12,000 sf, vivarium in basement
- Current occupants: Fruehauf (**SPT**), Zi (**CC**), Uchio (**CC**), Cozen (**CC**), Yu (HSCT)
- ETR TMA facility, Cell Processing Lab for HSCT Program

- Current CFCCC space comparable to other NCI CCs
- Space managed by CFCCC Administration
- Additional lab space of CFCCC members ~140,000 sf
- **Open space for recruitments: 6 bays, ~4,000 sf**
- **20,500 sf of new space in FLF-MIB in 2025**
- **Commitment of additional 5,000 sf for next 5 yrs.**


Lab space under CC Director authority



Research Space Support Index




Falling Leaves Foundation – Medical Innovation Building



Cancer Center clinical & clinical research footprint across Orange County



UCI Medical Center - Irvine



January 2024

UCI main campus

Chao Family
Comprehensive Cancer Center &
Ambulatory Care

Infusion Center opened: June 2024
All Services: July 2024

Specialty Hospital with
Emergency Department
Late 2025

Joe C. Wen & Family Center for
Advanced Care

First patients: April 2024

New Cancer Center Building on Irvine Campus



- 200,000 sf
- Radiation Oncology
- Advanced imaging
- Outpatient specialty pharmacy
- Multidisciplinary clinics
- 50 exam rooms
- Infusion Center (42 stations)
- Clinical research space
- Shelled floor for growth



UCI Health – Tenet Hospital Acquisition

Placentia-Linda Hospital (114 beds)




Lakewood Hospital (172 beds)



Los Alamitos Hospital (172 beds)



Fountain Valley Hospital (400 beds)




Organizational Capabilities *(Outstanding)*

CFCCC Institutional Status

趙 Chao Family Comprehensive Cancer Center

- A Center within Samueli College of Health Sciences
- Status superior to a Department
- Many members in the four COHS Schools:
 - Medicine
 - Nursing
 - Pharmacy & Pharmaceutical Sciences
 - Population & Public Health
- Numerous members in five other UCI Schools
- Cancer clinicians & clinical investigators practice within UCI Health
- CFCCC Director Van Etten serves as Associate Vice Chancellor for Cancer



Transitions in CFCCC Leadership



Miguel Villalona-Calero, MD
Deputy Director
(Chief, Heme/Onc Division)



Farshid Dayyani, MD, PhD
Associate Director for
Translational Science



Gary Deng, MD, PhD
Associate Director for
Integrative Oncology



Ursula Worsham, PhD
Associate Director for
Equity, Diversity & Inclusion



Marian Waterman, PhD
interim Associate Director
for Shared Resources



CFCCC LEAD Program

inaugural **Deputy Associate Directors**



Claudia Benavente, PhD
CRTEC



Wendy Cozen, DO, MPH
Pop Sci & Cancer Control



Aimee Edinger, PhD
Basic Science

inaugural **Assistant Program Leaders**



Xiaoyu Shi, PhD
BIDD



Roberto Tinoco, PhD
SPT




Gelareh Sadigh, MD
CC

New members of External Advisory Board



Louis Weiner, MD **Chair**
Georgetown Lombardi CCC



Primo (Lucky) Lara, MD
UC Davis CCC



Cheryl Willman, MD
Mayo CCC



Christopher Flowers, MD
MD Anderson CC



Kit Lam, MD PhD
UC Davis CCC



John Bushweller, PhD
U Virginia CC



Anita Kinney, PhD
Rutgers CINJ



John Pounardjian, MBA
Case Western CCC



Roshan Bastani, PhD
UCLA Jonsson CCC



Amelie Rameriz, DrPH MPH
UT Health San Antonio CC



Samuel Achilefu, PhD
UT Southwestern CC



Michael Birrer, MD PhD
Univ Arkansas CI



Kevan Shokat, PhD
UCSF Diller CCC

Clinician workforce recruitment for UCI Health network

Estimated need for cancer clinicians/clinical investigators: ~36 faculty

Heme-Onc: 22

Surg Onc: 8

Rad Onc: 6



Ann Arter, MD
HO/Thoracic Oncology
UCI (fellow)



Reza Nabavizadeh, MD
Urology
Mayo (faculty)



Poorya Vaidya, MD
HO/Melanoma
UCSD (fellow)



Michael O'Leary, MD
Surgery/Hepatobiliary
Loma Linda (faculty)



April Choi, MD
HO/GI cancer
Tufts (fellow)



Quoc-Anh Ho, MD
Radiation Oncology
Stanford (faculty)



Sayeh Lavasani, MD MS
Breast Medical Oncology
City of Hope (faculty)



Jorge Ramos-Perez, MD
Hematology/HSCT
City of Hope (fellow)




Jerica Lomax, MD
Neuro-oncology
UCI (fellow)



Brian Sworder, MD PhD
HO/Lymphoma
Stanford (faculty)



Nicole Foley, MD
HO/Lymphoma-HSCT
Wash U (fellow)



Miguel Villalona-Calero, MD
HO/Thoracic Oncology
City of Hope (faculty)



Priya Mitra, MD
Rad Onc
USC (faculty)



Shynam Srinivas, MD PhD
Interventional Radiology
UPMC (faculty)



Holly Yong, MD
Breast Surgical Oncology
Kaiser Permanente



Shirin Attarian, MD
HO/Head & Neck
LI Jewish (faculty)



Kelly Fairbairn, DO
Thoracic Surgical Oncology
MSKCC (fellow)



Mohammad Ziari, MD
Heme/Onc
City of Hope (faculty)










Polina Bellman, MD
HO/HSCT
U Kansas (fellow)



Eric Chen, MD
Rad Onc
Case Western (fellow)

Ongoing / Future Recruitments

-  Precision Medicine / Early Phase Clinical Trials Leader
-  Cancer Control faculty member
-  GU oncology translational researcher
-  Institute for Precision Health Director
-  Pathology Chair
-  Radiation Oncology Chair
-  Otolaryngology Chair

Cancer Focus (*Excellent to Outstanding*)

CFCCC extramural funding, AY 2021 vs. 2024


Funding Source	2021		2023		2024 (YTD)	
	Direct Costs	No. of Projects	Direct Costs	No. of Projects	Direct Costs	No. of Projects
Peer-Reviewed Projects						
NCI	\$10.7M	65	\$12.5M	85	\$13.5M*	86
Other NIH	\$13.8M	81	\$13.3M	86	\$14.8M	98
Other non-NIH	\$6.6M	52	\$7.0M	47	\$5.7M	37
Subtotal Peer-Reviewed	\$31.1M	198	\$32.8M	218	\$34.0M*	221
Non Peer-Reviewed Projects						
Industry	\$10.5M	139	\$10.8M	238	\$10.0M	237
Other	\$2.5M	31	\$2.2M	27	\$3.8M	38
Subtotal Non-Peer-Reviewed	\$13.0M	170	\$12.9M	265	\$13.8M	275
Grand Total	\$44.1M	368	\$45.7M	483	\$47.8M	496

* excluding P30 CCSG

CFCCC Research Programs



Systems, Pathways & Targets (SPT) Program (*Outstanding to Excellent*)

- 88 members across 6 UCI Schools and 19 Departments
- \$18.6M in grant funding, \$5.3M from the NCI
- Recruitment of numerous new members
- New research initiatives in Cancer Systems Biology, Cancer Metabolism




Biotechnology, Imaging & Drug Development (BIDD) Program (*Outstanding*)

- Merger of previous OIB and MDT Programs
- 90 members across 6 UCI Schools and 22 Departments
- \$16.5M in grant funding, \$5.0M from the NCI
- Emphasis on UCI excellence in “oncology physical sciences”
- **Need to identify new program co-leader**



Cancer Control (CC) Program (*Excellent to Very Good*)

- Refocused from previous Cancer Prevention, Outcomes & Survivorship (CPOS) Program
- 55 members across 7 UCI Schools and 18 Departments
- \$8.1M in grant funding, \$2.6M from the NCI
- New focus on cancer prevention and outcomes





Extramural Funding Profiles of CFCCC Research Programs

SPT (45)

BIDD (43)

CC (14)



Strategies to increase extramural peer-reviewed funding

- Assist current faculty, particularly early stage investigators, to get new extramural grants



Selma Masri, PhD
Assistant Professor
Biological Chemistry

ACC Pilot Project Awards 2018 & 2020



NIH NATIONAL CANCER INSTITUTE
R01 CA259370



Chris Halbrook, PhD
Assistant Professor
Mol Biol & Biochem

ACC Pilot Project Award 2021



NIH NATIONAL CANCER INSTITUTE
R01 CA283575



Kristen Kelly, MD
Professor
Dermatology

ACC Pilot Project Award 2020



NIH NATIONAL CANCER INSTITUTE
R01 CA259019



- Hire new faculty with existing extramural grants



Wendy Cozen, DO MPH
Professor
Medicine

R01 CA206019
R01 CA260615



Zhuoli Zhang, MD PhD
Professor
Radiological Sciences

R01 CA209886
R01 CA241532



Wei Li, PhD
Professor
Biological Chemistry

R01 CA193466

Program publications

BIDD

	# of Pubs	Inter	Intra	Inter-Inst	High IF (>9.4)
Jan. 2023 - Dec. 2023	170	24%	8%	59%	16%
Apr. 2023 - Mar. 2024	157	24%	7%	59%	16%
Sep. 2023 - Aug. 2024	161	24%	6%	62%	18%

CC


	# of Pubs	Inter	Intra	Inter-Inst	High IF (>9.4)
Jan. 2023 - Dec. 2023	152	20%	13%	72%	13%
Apr. 2023 - Mar. 2024	162	24%	15%	74%	12%
Sep. 2023 - Aug. 2024	174	22%	12%	73%	15%

SPT

	# of Pubs	Inter	Intra	Inter-Inst	High IF (>9.4)
Jan. 2023 - Dec. 2023	261	19%	21%	57%	26%
Apr. 2023 - Mar. 2024	233	23%	21%	59%	26%
Sep. 2023 - Aug. 2024	240	25%	19%	62%	25%



Link to dashboards



- EAB 2024 comments:

- Program Aims too broad and lack specificity
- Expand research focused on etiology, risk factors, and cancer screening
- Focus on priority cancers in the catchment area (CA)
- Increase the number of funded R01s
- More interventional research on areas of emphasis

- Need interventional research on cancer prevention

- RFP for CA-relevant research including clinical trials: 4 proposals funded at \$150K/yr x 2



Hari Keshava, MD
Thoracic Surgical Oncology

Low-dose CT scanning and cfDNA screening in nonsmoking relatives of NSCLC patients

- Need to continue to recruit additional extramurally funded members

- Another mid-career/senior faculty member (FY25 FTE request)

Transdisciplinary Collaboration & Coordination (*Outstanding*)

Critical CFCCC Cooperative Cancer Grant Renewals


Skin Biology Center (P30 AR075047; PI Andersen, SPT)

- Promoting discoveries in skin biology and disease
- CFCCC supporting a human skin tissue core and Enrichment Program
- Extensive interactions with Skin DOT and Melanoma systems biology group
- **Competing renewal application submitted in May 2023, awarded 04/01/24**
- **CFCCC providing institutional support for pilot projects**



Cancer Systems Biology (U54 CA217378; mPI Lander/Lowengrub/Lawson, SPT)

- One of 14 NCI Cancer Systems Biology Consortium Centers
- Focus on tumor heterogeneity and scRNASeq, quantitative models of tumor behavior
- Three interactive projects on breast cancer, melanoma, and leukemia
- **U54 program sundowned by the NCI**
- **P01 grant submitted May 2023: Merit score 36**
- **P01 A1 version submitted Jan 2024, Merit score 20**
- **Two R01 applications for leukemia project also submitted:**
 - **R01 CA280606 (Van Etten)- 3% score, funded 04/01/24**
 - **R01 CA293425 (Lowengrub & Van Etten)- 18% score**



CFCCC Collaborations


CFCCC Affiliates

- CHOC Children's
Site of all pediatric cancer care & clinical research
COG member, pediatric HCST and Phase I site
Active collaborative Working Groups in HSCT, AYA cancer, Education & Training, Research meeting quarterly
- VA Long Beach Health System
Joint faculty and CFCCC members
Training & educational collaborations
Research collaborations: NAVIGATE, Lung Cancer Precision Oncology



Other NCI CCs

- UC Heme Malignancy Consortium
Launched in 2014, rapid opening of trials across Consortium
8 trials completed, 9 open to accrual incl. **UCHMC1913 from UCI (accrued 24/30 pts)**
- UC Cancer Consortium
Leverage UC Care: ~25,000 new cancer patients annually
WGs on clinical pathways, precision oncology, virtual 2nd opinions
Disease groups: pancreatic cancer, lung cancer
Director Van Etten assumed Deputy UCCC Chair position in Oct. 2024
- Other NCI Cancer Centers
Partnerships with 12 other NCI-CCs through NCI Cancer Systems Biology Consortium
Many multi-PI grants with other centers, incl FLASH Radiotherapy P01



University of California
Hematologic Malignancies Consortium
UCD UCI UCLA UCSD UCSF




**CANCER SYSTEMS
BIOLOGY CONSORTIUM**

Disease-Oriented Teams: Interface between basic & clinical investigators

DOT functions


- Quarterly presentations by basic and clinical researchers
- Management of clinical trials portfolio
- Conduct 1st stage of scientific review
- DOT approval required for moving a trial to PRMC/IRB stage
- Bring new trial concepts forward
- Foster investigator-initiated trials



HSCT & Cell Therapy Program



Stefan Ciurea, MD
HSCT Program Leader



- Launched May 2020
- Only adult transplant program in Orange County
- FACT accredited: Mar 2022
- CalOptima Center of Excellence: May 2022
- Cell Processing Lab opened Q2 2024
- Recruited new heme malignancy physicians



Yaya Chu, PhD
Laboratory Director



Kiran Naqvi, MD
Myeloid leukemias




Cathy Coombs, MD
CLL




Brian Sworder, MD PhD
Lymphoma

Cumulative Patient Outreach - Sept FY25 YTD




- Continue transplant volume increase towards 100-120/yr
- Obtain COE designation from commercial payers
- Continue faculty recruitments (HSCT, ALL, myeloma)
- First HSCT IITs: ADAPT trial, autologous T cells vs BKV nephritis

Cumulative Stem Cell Transplants Trend



Immuno-Oncology




- Approved as designated commercial CAR-T site
- FACT-accredited for cell therapy
- cGMP cell manufacturing facility opened Q4 2023
- First CFCCC-developed therapy: novel chimeric antigen receptor targeting cancer-specific carbohydrates
- This therapy cures multiple cancers (breast, ovarian, prostate, lymphoma) in mice
- Accepted into **NEXT NCI Experimental Therapeutics Program**
 - manufacture & testing clinical grade material for first-in-human studies
- Target phase I trial opening: Q2 2025
- Next investigator-initiated trials: donor α -BK virus T-cells, haploidentical NK cells
- Recruiting two new immuno-oncology faculty




Mike Demetriou,
MD PhD




GlyTR1 + T cells + SKOV3



Day 8
(post-treatment)



Day 12
(post-treatment)



Jianhua Yu, PhD

Precision Oncology



- CFCCC & UCI Health have the largest early phase clinical trials program in OC

- Joined NCI ETCTN (with UPitt)



- Joined two industry networks




- Joined the Alliance NCTN group



- Activated genomics functionality in Epic and built interface with Caris to allow tumor genetic data to be analyzed

- Recruiting a Precision Therapeutics Director (with Center for Clinical Research)


- Expanding interactions with UC Cancer Consortium



Cancer Imaging



- Imaging at 100x resolution, 1/100th dose
- Applications in cancer:
 - Imaging
 - Cancer screening
 - Radiotherapy, incl. FLASH



- Commercialized in Lumitron Technologies
- Prototype machine being completed for DARPA
- Current machine is producing a Very High Energy Electron (VHEE) beam (25 MeV) suitable for preclinical studies of FLASH radiotherapy (Dr. Charlie Limoli, **BIDD**)
- 500 keV x-ray beam production achieved, enabling imaging studies in mice




Revolutionary X-Ray Innovation Set to Transform Cancer Treatment and Clinical Radiography

Lumitron Technologies advances the practical application of FLASH radiotherapy

February 20, 2023 12:45 PM Eastern Standard Time

IRVINE, Calif.--(BUSINESS WIRE)--Lumitron Technologies, Inc., a company pioneering the development of a unique x-ray system, HyperVIEW™ EBES, today announced its underlying accelerator technology has successfully generated electron beams that, for the first time, enable electron FLASH radiotherapy for a variety of next generation cancer treatments.

- UCI Office of Research, Schools of Medicine and Engineering, CFCCC, and UCI Advancement negotiating agreement for purchase of second-generation machine for research/clinical applications



Integrative Oncology / Whole Person Cancer Care



Susan Samuelli | Integrative Health Institute



Shaista Malik, MD, PhD, MPH
Director

- Susan Samuelli Integrative Health Institute (SSIHI) provides inpatient and outpatient integrative medicine services for patients with cancer
 - Acupuncture, massage, mindfulness, yoga, Tai-Chi, biofeedback, nutrition


- Expanded outpatient locations in Newport Beach & Laguna Hills

- **Recruited a clinician-scientist leader for integrative oncology program**
 - With the Samuelli Institute (endowed chair)

- **Secured institutional commitments for supportive oncology services**
 - dietary/nutrition, psychosocial, spiritual

- **Launching interventional clinical research in integrative oncology**

- Develop evidence-based approaches to integrative health in cancer
- ACC Pilot Project: UCI-21-33: Electroacupuncture for management of symptoms in AYA patients w/cancer
- R01 CA276212 PIs Chan (**CC**)/Acharya (**BIDD**): Repurposing Riluzole for augmenting BDNF in chemobrain



Gary Deng, MD, PhD

Clinical Research (*Outstanding*)

Stern Center for Cancer Clinical Trials & Research



Warren Chow, MD
Associate Director for
Clinical Science


130 Staff
26 open positions




Farshid Dayyani, MD, PhD
Medical Director, Stern Center

Administrative Director
Clinical Research Operations
Christine Hu

Clinical Trials Unit (CTU) (96)
Assistant Director Clinical Trials Unit TBN (46)
Assistant Director Clinical Trials Unit TBN (46)



Clinical Trial Revenues



Source	\$
Industry	8,212,439
Institutional Support	2,373,042
Gifts & Endowments	497,490
CCSG	349,166
National Cooperative Group	258,780
External	776,383
Total	12,467,299

Protocol Review & Monitoring Committees
DOTs: Disease-Oriented Teams (5)
DSMB: Data & Safety Monitoring Board
PRMC: Protocol Review & Monitoring Committee

CFCCC Clinical Research summary



Warren Chow, MD
Associate Director for
Clinical Science



Farshid Dayyani, MD, PhD
Medical Director, Stern Center for
Cancer Clinical Trials & Research



Arash Rezazadeh, MD
Co-Chair, Protocol Review &
Monitoring Committee



John Fruehauf, MD, PhD
Chair, Data & Safety
Monitoring Board



Christine Hui, MPH
Administrative Director for
Clinical Research Operations


The GOOD:

- Joined NCI ETCTN (UPitt); UCI had the 3 top accruers for 2023
- eRegulatory binder system (Complion)
- Increased Stern Center efficiencies
- Decreased time to trial activation
- New ClinROC oversight committee
- Two clean not-for-cause FDA audits
- Excellent accrual of URM and older adults
- Record number of IITs open to accrual (18)
- Robust accrual to interventional trials (670 in CY23)




The BAD:

- Static accruals to interventional treatment trials (300 in CY23)
- Decrease in accrual of women to treatment trials (~40% in CY23)




Clinical Research: Corrective Action Plans



Treatment trial accruals:

- Increase referrals from outside groups: OPN Healthcare, Oncology Institute for Hope, VAH, Kaiser-Permanente
- Opening several IITs with potential for high accrual: HSCT, gastric cancer, prostate cancer
- Reform of DOT SOPs to better match trials with patient population
- Reorganization of Phase 1 infrastructure with recruitment of Director for early phase clinical trials
- Targeted recruitment of clinician-investigators in diseases with low accrual (H&N, melanoma, Gyn)




Accrual of women:

- Open more breast and Gyn trials targeting our patient population
- Recruit a medical oncologist specializing in Gyn cancers to oversee the Gyn DOT and clinical trials portfolio

Community Outreach & Engagement (*Outstanding to Excellent*)

Community Outreach & Engagement



Understanding our Orange County community in detail




General

Specific

Standard OC-wide Analysis

Racial & Ethnic Diversity

Asian Ethnic Diversity (23% of OC)




Proposed new Catchment Area



Orange County

Total # patients seen 4,869
 # of analytic cases 3,649
 % of analytic cases that reside in OC 70%




Patient Residence
 Low High

Current: OC

White	38%
Hispanic/Latino (any race)	34%
Asian	23%
Black/African American	2.3%
Native Hawaiian/Pacific Islander	0.4%
American Indian or Alaska Native	0.2%
Two or More Races	4%
TOTAL population	3.2 million

+UCI Health PSAs/SSAs

Total # patients seen 4,869
 # of analytic cases 3,649
 % of analytic cases that reside in OC+ 80%



Patient Residence
 Low High

Expanded: OC+UCI Health PSAs/SSAs

White	33%
Hispanic/Latino (any race)	37%
Asian	22%
Black/African American	3%
Native Hawaiian/Pacific Islander	0.3%
American Indian or Alaska Native	0.2%
Two or More Races	4%
TOTAL population	4.6 million

Adding OC-adjacent includes:

+5.4% Black/African American
 +45% Hispanic/Latino

Community Outreach & Engagement – Summary

- Active and engaged Community Equity Board
- Regular bilateral interactions with CFCCC Research Programs leading to new grants focused on Catchment Area
 - R37 CA266042 “*Defining Mechanisms of Genome Rearrangements in Ph-like ALL to Determine Predictive Markers in High-Risk Hispanic Populations*”, PI Pannunzio (SPT)
- Multiple new extramural grants addressing Catchment Area cancer health disparities

- CFCCC/Cal State U Fullerton P20 Cancer Health Equity Research Partnership



- UCI Family Health Center awarded \$500K from HRSA for *Accelerating Cancer Screening*



- Define Catchment Area priorities: cancer health disparities
- Expand the *Advancing Cancer Care Together* program with OC FQHCs (\$5M CalOptima grant)
- Improve data collection and analysis of outcomes, starting with UCI FQHCs
- Potential collaborations with other NCI CCs in OC (e.g. City of Hope)
- Appointed COE Liaisons in the CFCCC Research Programs



COE Liaisons



Shawn Griffin, Pharm D
Systems, Pathways &
Targets



Gelareh Sadigh, MD
Cancer Control



Darci Trader, PhD
Biotechnology, Imaging
& Drug Development

Cancer Research Training & Education (*Outstanding*)

Cancer Research Training & Education



Edward Nelson, MD
Associate Director for Cancer
Research Training & Education



PRE-BACCALAUREATE

UNDERGRADUATE

GRADUATE/MED STUDENTS

POST-DOCTORAL

FACULTY

ANTI-CANCER CHALLENGE

HS YOUTH SCIENCE FELLOWSHIP

ANNUAL & PROGRAM RETREATS | ANNUAL SYMPOSIA & CONFERENCES | DEI EDUCATION

ANNUAL CHAO FAMILY LECTURESHIP

R25s: BIG DATA SCIENCE & CANCER | INTERDISCIPLINARY CAREERS | CANCER SYSTEMS BIOLOGY

SHARED RESOURCE TECH TALKS AND TRAININGS

CANCER-RELATED UCI T32 AWARDS (8)

ACS IRG MINORITY SUPPLEMENT

ONCOLOGY SUMMER INTERNSHIP

CFCCC MET

CME > 20 EVENTS W/CFCCC

P20 CSUF/UCI CANCER RESEARCH EXPERIENCE PROGRAM

CFCCC CLINICAL TRIALS BOOTCAMP

UCI NSF CAREER INSTITUTE

COSMOS

MSTP

GRAND ROUNDS

ICTS: KL2 (2/4), TL1 NRSA (6/9), T35 SMART PROGRAM (2/8)

CANCER-ASSOC.: 17 RESIDENCIES, 11 CLINICAL FELLOWSHIPS

NIH R01 BOOTCAMP

SUMMER SURGICAL FELLOWSHIPS: UROLOGY, SURG ONC, SURGERY

PRIME-LC

ICTS K CLUB

PHYSICIAN SCI. TRAINING PRG.

SCHOOL VISITS

BIO 199: UROP SURP

LEAD-ABC

NIH RESUBMISSION PROGRAM

CANCER CURR. 5 class > 20 CC Members

QUARTERLY CAREER FAIR

NIH F AWARDS

VANGUARD GROUP (CCBS)

COLLEGES AGAINST CANCER

GPS STEM | RIPS | ANNUAL CAREER WORKSHOP

CAREER DEV. AWARDS 7 Fs, 2Ks

UCI BEALL APPLIED INNOVATION

ASSOCIATION FOR WOMEN IN SCIENCE

CFCCC

CFCCC + Partners

UCI

Plan to Enhance Diversity

Equity, Diversity and Inclusion Steering Committee



CHAIR
Associate Director EDI
Ursula Worsham, PhD



UNIVERSITY



Vice Chancellor for Diversity Equity & Inclusion and UCI Chief Diversity Officer
Dyonne Bergeron, EdD



Assistant Vice Chancellor Equity, Diversity & Inclusion
Marguerite Bonous-Hammarth, PhD

COHS SCHOOLS



School of Medicine Assistant Dean DEI
Ursula Worsham, EdD



School of Nursing DEI Officer
TBD



School of Pharmacy DEI Officer
Mahtab Jafari, Pharm D



Program in Pop. Science & Public Health DEI Officer
Sora Tanjasiri, DrPH, MPH (CC)

TRAINING & EDUCATION



Associate Director CRTEC
Edward L. Nelson, MD (BIDD)



Co-Director, LEAD ABC
Carrol Major, MD
OB/Gyn



Co-Director, LEAD ABC
Candace Taylor Lucas, MD
Pediatrics



Director, PRIME-LC
Charles P. Vega, MD

COMMUNITY OUTREACH



Associate Director COE
Sora Tanjasiri, DrPH, MPH (CC)

CATCHMENT AREA



Associate Professor of Pharmaceutical Sciences
Claudia Benavente, PhD (SPT Program)



School of Medicine Office of Belonging, Equity & Empowerment
Xavier Hernandez, PhD



Professor Epidemiology & Biostatistics
Karen Edwards, PhD (CC Program)



Professor of Family Medicine
Juliet McMullin, PhD



Professor Epidemiology & Biostatistics
Sunmin Lee, PhD (CC)

CFCCC Plan to Enhance Diversity

- CFCCC CAO with extensive experience in DEI administration and operational leadership
- CFCCC Director of Admin Programs supporting DEI efforts
- EDI Steering Committee formed Sept 2022
- Leveraging numerous ongoing SOM and UCI Diversity programs
- Anti-Cancer Challenge 2023-24 Pilot Project categories for Underrepresented Investigators, Re-entry after family care
- Pilot Pulse Survey (Jan 2023) on Diversity, Inclusion & Belonging
- CFCCC LEAD program for leadership development
- **Creation of CFCCC Plan and Metrics**



Melanie Funes, PhD
CAO & Associate Director
Administration & Finance



April Bagaporo, MBA
Director for Administrative Programs



Philanthropy

CFCCC Philanthropy - summary

Dedicated Cancer Advancement Team (6 FTE)

- Jenn Sarrail, Denice Lanuti, Jared Bigman, Tim Preletz, Joy Kliewer, Freddy Vega
- Last 7 yrs: >\$50M raised, endowment increased from \$5M to \$32M, 6 new endowed chairs




Executive Director of
Development (Cancer)
Angelique Andrulaitis

UCI Brilliant Future Campaign

- UCIMC Irvine and FLF-MIB: Raised \$26M towards cancer building and associated space
- Research Endowments: Raised ~\$25M to support cancer research



UCI Anti-Cancer Challenge



- Eight-year fundraising total ~\$6.3M
- 100% dedicated to cancer research
- Overall ROI on pilot projects is ~17:1
- Collaborative agreement with CHOC
- Aldrich Park event October 5, 2024
- 2024 ACC fundraising: >\$1,500,000
- RFP will be released in December
- Gina Lee award



11th Annual Chao Lecturer in Cancer: Feb. 27th, 2025



Karen M. Winkfield, MD, PhD

Ingram Professor of Cancer Research
Professor of Radiation Oncology
Vanderbilt University

Executive Director, Meharry-Vanderbilt Alliance
Member, National Cancer Advisory Board

Research: Design & implementation of programs to reduce socioeconomic barriers contributing to disparate health outcomes in cancer



Questions?

Recognition: Edward L. Nelson, MD

We would not be where we are today without Ed Nelson...



CFCCC new cancer patients

